Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
CRISPR Therapeutics AG (CRSP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/09/2023 |
4
| George Simeon (Director) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 13,000 options to buy
@ $62.59, valued at
$813.7k
|
|
| 06/09/2023 |
4
| Behbahani Ali (Director) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 13,000 options to buy
@ $62.59, valued at
$813.7k
|
|
| 06/09/2023 |
4
| Treco Douglas A (Director) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 13,000 options to buy
@ $62.59, valued at
$813.7k
|
|
| 06/09/2023 |
4
| High Katherine A (Director) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 13,000 options to buy
@ $62.59, valued at
$813.7k
|
|
| 06/09/2023 |
4
| Greene John (Director) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 13,000 options to buy
@ $62.59, valued at
$813.7k
|
|
| 06/09/2023 |
4
| Fleming Harold Edward (Director) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 13,000 options to buy
@ $62.59, valued at
$813.7k
|
|
| 06/09/2023 |
4
| Fardis Maria (Director) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 13,000 options to buy
@ $62.59, valued at
$813.7k
|
|
| 06/01/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 7,301 shares
@ $63.6149, valued at
$464.5k
Sold 5,999 shares
@ $64.4577, valued at
$386.7k
Sold 9,300 shares
@ $65.63, valued at
$610.4k
Sold 2,400 shares
@ $66.8338, valued at
$160.4k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 05/25/2023 |
4
| Morrow Phuong Khanh (Chief Medical Officer) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 2,527 shares
@ $65.91, valued at
$166.6k
Exercised 6,938 restricted stock units
@ $0 |
|
| 04/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/31/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 19,719 shares
@ $44.3733, valued at
$875k
Sold 5,281 shares
@ $44.7844, valued at
$236.5k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 03/14/2023 |
4
| Prasad Raju (CFO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 40,000 restricted stock units
@ $0
Granted 100,000 options to buy
@ $45.15, valued at
$4.5M
|
|
| 03/14/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 5,358 shares
@ $43.22, valued at
$231.6k
Paid exercise price by delivering 4,086 shares
@ $43.22, valued at
$176.6k
Exercised 11,833 restricted stock units
@ $0
Granted 188,000 options to buy
@ $43.22, valued at
$8.1M
Granted 77,000 restricted stock units
@ $0
Exercised 9,000 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| KASINGER JAMES R. (General Counsel and Secretary) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 1,283 shares
@ $43.22, valued at
$55.5k
Paid exercise price by delivering 1,022 shares
@ $43.22, valued at
$44.2k
Exercised 2,833 restricted stock units
@ $0
Granted 40,000 options to buy
@ $43.22, valued at
$1.7M
Granted 22,000 restricted stock units
@ $0
Exercised 2,250 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Morrow Phuong Khanh (Chief Medical Officer) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 44,620 options to buy
@ $43.22, valued at
$1.9M
Granted 22,000 restricted stock units
@ $0 |
|
| 03/14/2023 |
3
| Prasad Raju (CFO) has filed a Form 3 on CRISPR Therapeutics AG |
| 03/01/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 10,180 shares
@ $47.7122, valued at
$485.7k
Sold 13,720 shares
@ $48.5725, valued at
$666.4k
Sold 1,100 shares
@ $49.1986, valued at
$54.1k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 02/22/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/22/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/22/2023 |
4
| KASINGER JAMES R. (General Counsel and Secretary) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 1,950 shares
@ $48.26, valued at
$94.1k
Exercised 3,825 restricted stock units
@ $0 |
|
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/30/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 20,366 shares
@ $40.8126, valued at
$831.2k
Sold 4,634 shares
@ $41.4546, valued at
$192.1k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 12/08/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Exercised 58,233 options to buy
@ $1.81, valued at
$105.4k
|
|
| 12/06/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 19,401 shares
@ $52.26, valued at
$1M
Exercised 40,000 restricted stock units
@ $0 |
|
| 12/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 17,118 shares
@ $53.5837, valued at
$917.2k
Sold 5,572 shares
@ $54.8453, valued at
$305.6k
Sold 2,310 shares
@ $55.4039, valued at
$128k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 10/28/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 2,500 shares
@ $52.732, valued at
$131.8k
Sold 4,000 shares
@ $54.0635, valued at
$216.3k
Sold 11,312 shares
@ $54.9659, valued at
$621.8k
Sold 7,188 shares
@ $55.6946, valued at
$400.3k
Exercised 19,582 options to buy
@ $16.21, valued at
$317.4k
Exercised 5,418 options to buy
@ $19.12, valued at
$103.6k
|
|
| 10/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/12/2022 |
4
| Smith Brendan (CFO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 14,000 options to buy
@ $61.65, valued at
$863.1k
|
|
| 10/12/2022 |
4
| Morrow Phuong Khanh (Chief Medical Officer) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 9,380 options to buy
@ $61.65, valued at
$578.3k
|
|
| 10/12/2022 |
4
| KASINGER JAMES R. (General Counsel and Secretary) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 14,000 options to buy
@ $61.65, valued at
$863.1k
|
|
| 09/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/31/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 4,073 shares
@ $66.1405, valued at
$269.4k
Sold 20,764 shares
@ $66.975, valued at
$1.4M
Sold 163 shares
@ $67.64, valued at
$11k
Exercised 25,000 options to buy
@ $16.21, valued at
$405.3k
|
|
| 08/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|